๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for MRD

Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) NCT07120698Phase 22 sites๐Ÿ“ Guangzhou๐Ÿ“ Chengdu Guangdong Association of Clinical Trials ยท Tests: Sintilimab CtDNA Based MRD Testing for NAC Monitoring in TNBC NCT06230185n/a14 sites๐Ÿ“ Tucson๐Ÿ“ Aurora๐Ÿ“ Washington D.C. Personalis Inc. MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer NCT07894458NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer NCT07034742EARLY Phase 11 site๐Ÿ“ Beijing Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ ยท Tests: Intraperitoneal chemotherapy PLUS systemic chemotherapy MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma NCT07106736Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: BCMA CAR-T, GPRC5D/CD3 BiTEs Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT NCT05623267Phase 2, Phase 31 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Sugemalimab, Placebo A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib NCT06284486Phase 1, Phase 24 sites๐Ÿ“ Baltimore๐Ÿ“ Boston๐Ÿ“ New York M.D. Anderson Cancer Center ยท Tests: Venetoclax, Revumenib Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma NCT07891923Phase 22 sites๐Ÿ“ Navi Mumbai๐Ÿ“ Navi Mumbai Tata Memorial Centre ยท Tests: Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone) The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial. NCT06477991n/a1 site๐Ÿ“ Kunming Yunnan Cancer Hospital ยท Tests: Tireilizumab๏ผˆPD-1 inhibitor๏ผ‰ Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) NCT06005818Phase 21 site๐Ÿ“ Birmingham University of Alabama at Birmingham ยท Tests: Pembrolizumab injection Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia NCT03737955Phase 21 site๐Ÿ“ Seattle University of Washington ยท Tests: Gemtuzumab Ozogamicin, Quality-of-Life Assessment, Bone Marrow Aspiration, Biospecimen Collection Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children NCT06099366Phase 213 sites๐Ÿ“ Seoul๐Ÿ“ Seoul๐Ÿ“ Yangsan Hee Young Ju ยท Tests: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate, Consolidation: Vincโ€ฆ MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma NCT07409454Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: anti-BCMA/CD3 bispecific antibody Discontinuation Study NCT05866757NA1 site๐Ÿ“ Cork University College Cork ยท Tests: Discontinuation of maintenance treatment Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) NCT06993675Phase 22 sites๐Ÿ“ New Haven๐Ÿ“ Rochester Noffar Bar ยท Tests: Talquetamab, Teclistamab Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease NCT06878131n/a1 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Colorectal Cancer Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML NCT07500441n/a1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Individualized Digital PCR (dPCR) monitoring IMMUNOPLANT for Newly Diagnosed Multiple Myeloma NCT06376526Phase 21 site๐Ÿ“ Miami Dickran Kazandjian, MD ยท Tests: Linvoseltamab Mosunetuzumab for CLL MRD Clearance NCT07052695Phase 1, Phase 22 sites๐Ÿ“ Boston๐Ÿ“ Boston Inhye Ahn ยท Tests: Mosunetuzumab, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD NCT07104058NA1 site๐Ÿ“ Beijing Luo Yaping ยท Tests: 68Ga-FAPI PET / CT ctDNA in Cutaneous Squamous Cell Carcinoma NCT06875609n/a1 site๐Ÿ“ Boston Massachusetts Eye and Ear Infirmary ยท Tests: Blood and Tissue Collection Motixafortide for MRD Sensitization in AML NCT07392970Phase 21 site๐Ÿ“ St Louis Washington University School of Medicine ยท Tests: Motixafortide Tirzepatide Weight Loss for MRD+ Early Breast Cancer NCT06517212Phase 21 site๐Ÿ“ Dallas Baylor Research Institute ยท Tests: Tirzepatide CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT NCT07441291Phase 31 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CAR-T, DLI A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naรฏve, High-Risk CLL/SLL Patients NCT07671378Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Zanubrutinib and sonrotoclax Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults NCT04179929NA108 sites๐Ÿ“ Badalona๐Ÿ“ A Coruรฑa๐Ÿ“ Albacete PETHEMA Foundation ยท Tests: Pediatric-type of chemotherapy, allogeneic HSCT UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 NCT05535855Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19 Directed CAR T Cell EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) NCT06401421n/a58 sites๐Ÿ“ Anchorage๐Ÿ“ Palo Alto๐Ÿ“ Torrance Exact Sciences Corporation ยท Tests: ctDNA MRD test MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib NCT07463651Phase 32 sites๐Ÿ“ Suzhou๐Ÿ“ Shanghai The First Affiliated Hospital of Soochow University ยท Tests: Gilteritinib, Sorafenib A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS NCT05788679Phase 21 site๐Ÿ“ Stockholm Karolinska University Hospital ยท Tests: Azacitidine, Donor lymphocytes, Tapering of immune suppression
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy